Core Viewpoint - The shareholder meeting of Beijing Innotech Biotechnology Co., Ltd. was held on May 22, 2025, with all proposed resolutions passing successfully, indicating strong shareholder support and compliance with legal requirements [1][2][3]. Meeting Details - The meeting took place at the conference room on the 7th floor of Building 2, No. 1 Haiying Road, Fengtai District, Beijing [1]. - A total of 64 ordinary shareholders attended, holding 72,974,432 voting rights, which accounted for 54.3185% of the company's total voting rights [1]. Voting Results - All non-cumulative voting proposals were approved with significant majority support: - Proposal votes: 72,937,802 in favor (99.9498%), 34,230 against (0.0469%), and 2,400 abstentions (0.0033%) [1][2]. - Similar voting patterns were observed across multiple proposals, consistently showing over 99% approval from ordinary shareholders [2][3]. Legal Compliance - The meeting's convening and voting procedures adhered to the requirements set forth by the Company Law of the People's Republic of China and the company's articles of association, ensuring the legitimacy of the proceedings [1][3].

Core Viewpoint - The legal opinion confirms the legitimacy of the 2024 annual general meeting of Beijing Innotech Biotechnology Co., Ltd., ensuring compliance with relevant laws and regulations [1][11]. Group 1: Meeting Procedures - The notice for the 2024 annual general meeting was properly issued, detailing the time, location, agenda, and registration methods for shareholders [3][4]. - The meeting was held at the specified location and was presided over by the chairman, Ye Fengguang [4][5]. Group 2: Attendance and Qualifications - A total of 7 shareholders attended the meeting in person, representing 68,709,082 shares, which is a significant portion of the voting rights [6]. - 57 shareholders participated in the online voting, with their qualifications verified by the Shanghai Stock Exchange [6][11]. Group 3: Voting Procedures and Results - The meeting utilized both on-site and online voting methods, with results being monitored and counted by designated personnel [7][11]. - Various resolutions were passed with overwhelming support, including votes where over 99% of the attending shareholders approved the proposals [7][10].

北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 2024 年年度股东大会的 法律意见书 2025 年 5 月 北京市中伦律师事务所 关于北京英诺特生物技术股份有限公司 2024 年年度股东大会的 法律意见书 致：北京英诺特生物技术股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京英诺特生物技术股份有 限公司（以下简称"公司"）委托，指派本所律师对公司 2024 年年度股东大会（以 下简称"本次股东大会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以 下简称"中国证监会"）《上市公司股东会规则》（以下简称"《股东会规则》"）等 现行有效的法律、法规、规范性文件以及《北京英诺特生物技术股份有限公司章 程》（以下简称"《公司章程》"）的规定而出具。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、准 ...

证券代码：688253 证券简称：英诺特 公告编号：2025-024 北京英诺特生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 64 | | --- | --- | | 普通股股东人数 | 64 | | 2、出席会议的股东所持有的表决权数量 | 72,974,432 | | 普通股股东所持有表决权数量 | 72,974,432 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 54.3185 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 54.3185 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 （一） 股东大会召开的时间：2025 年 5 月 22 日 （二） 股东大会召开的地点：北京市 ...

Core Viewpoint - Huatai United Securities is acting as the sponsor for Beijing Innotech Biotechnology Co., Ltd. during its initial public offering, providing continuous supervision and guidance to ensure compliance with relevant regulations and standards. Group 1: Continuous Supervision Work - The sponsor has established and effectively implemented a continuous supervision work system, including a detailed work plan [1] - A continuous supervision agreement has been signed with Innotech, clarifying the rights and obligations of both parties during the supervision period [1] - The sponsor has conducted regular communication, site inspections, and due diligence to carry out continuous supervision [2] Group 2: Compliance and Governance - Innotech has not reported any violations or breaches of commitments during the supervision period [1][2] - The company has established and effectively executed its corporate governance system, including rules for shareholder meetings and board meetings [2] - The sponsor has verified that Innotech's internal control systems comply with relevant regulations [2] Group 3: Financial Performance - Innotech's operating income for the reporting period reached approximately RMB 621.39 million, a year-on-year increase of 29.99% [16] - The net profit attributable to shareholders was approximately RMB 246.86 million, reflecting a growth of 41.92% compared to the previous year [16] - The gross profit margin for the main business was 80.12%, indicating a strong position in the market [15] Group 4: Research and Development - The company has increased its R&D investment, with total R&D expenditures amounting to approximately RMB 97.17 million, an increase of 82.95% year-on-year [22] - Innotech has established multiple R&D centers and developed six major technology platforms to enhance its innovation capabilities [18] - The company has obtained several domestic and international medical device registration certificates, indicating progress in its product development [22] Group 5: Market Position and Risks - Innotech focuses on the in vitro diagnostic industry, which is characterized by rapid technological advancements and high competition [9] - The company has a strong product line in respiratory pathogen detection, which constitutes a significant portion of its revenue [12] - Potential risks include technological obsolescence, regulatory changes, and market competition, which could impact the company's future performance [10][11][12]

华泰联合证券有限责任公司 关于北京英诺特生物技术股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司名称：北京英诺特生物技术股份有限 | | --- | --- | | | 公司 | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | | 保荐代表人姓名：郑明欣 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科创 板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以下简 称"华泰联合"或"保荐机构"）作为北京英诺特生物技术股份有限公司（以下简称 "英诺特"或"公司"）首次公开发行股票的保荐机构，对英诺特进行持续督导，并出 具 2024 年度（以下简称"本报告期"或"报告期"）持续督导跟踪报告： 一、持续督导工作情况 | 序号 | 项目 | 持续督导工作情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度， | 保荐机构已制定并严格执行持续督导 | | 1 | 并针对具体的持续督导工作制定相应的工 | 工作制度，已根据公司的 ...

Group 1 - The A-share market saw a collective decline on May 16, while the Sci-Tech Innovation Pharmaceutical sector rebounded, with the Sci-Tech Innovation Pharmaceutical ETF (588860) rising by 0.16% [1] - Notable stocks in the sector included Maiwei Biotech-U, which increased by over 5%, along with Shouyao Holdings-U, KQ Biotech, Innotec, CanSino, and Baotai, all of which experienced gains [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals and related fields to reflect the overall performance of representative companies in the sector [1] Group 2 - According to CMB International, the optimization of centralized procurement policies in mainland China provides hospitals and enterprises with more flexibility and autonomy, benefiting leading prescription drug companies [2] - The anticipated implementation of favorable policies, such as the 2025H2 medical insurance category, is expected to accelerate industry consolidation, with the sector's valuations remaining at historical lows [2] - The recommendation is to focus on innovative drug targets with high growth potential or clear breakeven timelines after short-term sentiment stabilizes [2]

Group 1 - The core viewpoint of the article highlights that Innotech's stock closed at 31.5 yuan, down 1.25%, with a rolling PE ratio of 21.92 times and a total market capitalization of 4.298 billion yuan [1] - Innotech operates in the bioproducts industry, which has an average PE ratio of 57.79 times and a median of 38.07 times, placing Innotech at the 34th position in the industry ranking [1] - As of the first quarter of 2025, four institutions held shares in Innotech, with a total of 5.2561 million shares valued at 183 million yuan [1] Group 2 - Innotech's main business focuses on the research, production, and sales of POCT rapid diagnostic products, primarily targeting respiratory pathogen detection, while also covering areas such as reproductive health, digestive tract, and hepatitis testing [1] - The latest performance report for the first quarter of 2025 shows that Innotech achieved an operating revenue of 207 million yuan, a year-on-year decrease of 26.51%, and a net profit of 95.2897 million yuan, down 34.77%, with a gross profit margin of 83.12% [1]

北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 22 日 1 / 30 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料 北京英诺特生物技术股份有限公司 2024 年年度股东大会会议资料目录 | 年年度股东大会会议须知 2024 3 | | --- | | 2024 年年度股东大会会议议程 5 | | 年年度股东大会会议议案 2024 7 | | 议案一：关于公司 2024 年年度报告及其摘要的议案 7 | | 议案二：关于公司 年度财务决算报告的议案 8 2024 | | 议案三：关于公司 2025 年度财务预算报告的议案 9 | | 议案四：关于 年度董事会工作报告的议案 10 2024 | | 议案五：关于 2024 年度监事会工作报告的议案 11 | | 议案六：关于公司 2024 年年度利润分配方案的议案 12 | | 议案七：关于续聘公司 2025 年度审计机构的议案 13 | | 议案八：关于 2025 年度董事薪酬方案的议案 14 ...

Financial Performance - The company achieved total operating revenue of 621.39 million, representing a year-on-year growth of 29.99% [2][5] - The net profit attributable to shareholders was 246.86 million, reflecting a year-on-year increase of 41.92% [2][5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 217.75 million, with a year-on-year growth of 48.08% [2][5] Cash Flow - The net cash flow from operating activities was 305.46 million, showing a year-on-year increase of 17.55% [5] - The net cash flow from investing activities was -63.07 million, an improvement from -429 million in the previous year [5] - The net cash flow from financing activities was -103 million, a decrease of 58.27 million year-on-year [5] Assets and Liabilities - The net assets attributable to shareholders at the end of 2024 were 1,993.39 million, an increase of 8.22% compared to the end of 2023 [1] - Total assets reached 2,212.46 million, reflecting a year-on-year growth of 7.11% [1] - Cash and cash equivalents increased by 84.86% compared to the previous year, with a rise in proportion to total assets by 5.85 percentage points [5] Company Overview - The company, Beijing Innotech Biotechnology Co., Ltd., focuses on the research, development, production, and sales of POCT rapid diagnostic products [6] - It specializes in the field of in vitro diagnostics, particularly in respiratory pathogen detection, and has developed multiple detection technologies [6] - The company has established a significant market position in respiratory pathogen detection, with products recognized by major children's hospitals [6] Research and Development - The company has built six major technology platforms, including immunochromatography and nucleic acid molecular detection [7] - R&D investment reached 97.17 million in 2024, a year-on-year increase of 82.95%, accounting for 15.64% of operating revenue [7]